Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients

Back

ESC Professional Premium Access

Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients

Session: Pharmacology in coronary artery disease

Topic: Pharmacotherapy

Speaker: Professor K. Trusinskis (Riga, LV)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Karlis Trusinskis

Paul Stradins Clinical University Hospital, Riga (Latvia)

1 presentation

0 follower

6 more presentations in this session

Optimal antiplatelet therapy for patients after antiplatelet therapy-induced gastrointestinal bleeding: when to resume?

Speaker: Professor R. Huang (Beijing, CN)

A meta-analysis on the efficacy of ticagrelor monotherapy after 3 months of dual antiplatelet therapy vs ticagrelor plus aspirin dual therapy on patients with ACS who underwent PCI

Speaker: Doctor L. Galera (Manila, PH)

Efficacy and safety of under-dose non-vitamin K antagonist oral anticoagulant with atrial fibrillation undergoing PCI: Insights from a nationwide population-based cohort study

Speaker: Ms G. Youk (Busan, KR)

Interplay among proton pump inhibitors, platelet reactivity and CYP2C19 genotyping in clopidogrel-treated patients after drug-eluting stent implantation

Speaker: Assistant Professor J. Kim (Seoul, KR)

Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study

Speaker: Professor L. Wolff Gowdak (Sao Paulo, BR)

Access the full session

Pharmacology in coronary artery disease

Speakers: Professor K. Trusinskis, Professor R. Huang, Doctor L. Galera, Ms G. Youk, Assistant Professor J. Kim...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients

About the speaker

Professor Karlis Trusinskis

6 more presentations in this session

Optimal antiplatelet therapy for patients after antiplatelet therapy-induced gastrointestinal bleeding: when to resume?

A meta-analysis on the efficacy of ticagrelor monotherapy after 3 months of dual antiplatelet therapy vs ticagrelor plus aspirin dual therapy on patients with ACS who underwent PCI

Efficacy and safety of under-dose non-vitamin K antagonist oral anticoagulant with atrial fibrillation undergoing PCI: Insights from a nationwide population-based cohort study

Interplay among proton pump inhibitors, platelet reactivity and CYP2C19 genotyping in clopidogrel-treated patients after drug-eluting stent implantation

Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study

Access the full session

Pharmacology in coronary artery disease

About the event

ESC Congress 2023

ESC 365 is supported by